Dashboard
Manage Tickers

KALVKalVista Pharmaceuticals, Inc.

Nasdaq kalvista.com


$ 14.99 $ -0.28 (-1.84 %)    

Wednesday, 17-Jul-2024 15:59:44 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 482.23 $ -14.57 (-2.94 %)
DIA $ 412.29 $ 2.27 (0.55 %)
SPY $ 557.05 $ -7.92 (-1.4 %)
TLT $ 94.21 $ 0.02 (0.02 %)
GLD $ 227.29 $ -1.06 (-0.46 %)
$ 14.97
$ 15.09
$ 14.93 x 200
$ 0.00 x 0
$ 14.81 - $ 15.15
$ 7.21 - $ 16.88
291,285
na
550.7M
$ 1.04
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 07-11-2024 04-30-2024 10-K
2 03-11-2024 01-31-2024 10-Q
3 12-07-2023 10-31-2023 10-Q
4 09-07-2023 07-31-2023 10-Q
5 07-07-2023 04-30-2023 10-K
6 03-09-2023 01-31-2023 10-Q
7 12-08-2022 10-31-2022 10-Q
8 09-08-2022 07-31-2022 10-Q
9 07-07-2022 04-30-2022 10-K
10 03-10-2022 01-31-2022 10-Q
11 12-09-2021 10-31-2021 10-Q
12 09-09-2021 07-31-2021 10-Q
13 07-13-2021 04-30-2021 10-K
14 03-11-2021 01-31-2021 10-Q
15 12-10-2020 10-31-2020 10-Q
16 09-14-2020 07-31-2020 10-Q
17 07-01-2020 04-30-2020 10-K
18 03-10-2020 01-31-2020 10-Q
19 12-03-2019 10-31-2019 10-Q
20 09-09-2019 07-31-2019 10-Q
21 07-16-2019 04-30-2019 10-K
22 03-14-2019 01-31-2019 10-Q
23 12-14-2018 10-31-2018 10-Q
24 09-14-2018 07-31-2018 10-Q
25 07-30-2018 04-30-2018 10-K
26 03-16-2018 01-31-2018 10-Q
27 12-14-2017 10-31-2017 10-Q
28 09-14-2017 07-31-2017 10-Q
29 07-27-2017 04-30-2017 10-K
30 03-16-2017 01-31-2017 10-Q
31 11-08-2016 09-30-2016 10-Q
32 08-12-2016 06-30-2016 10-Q
33 05-12-2016 03-31-2016 10-Q
34 03-30-2016 12-31-2015 10-K
35 11-12-2015 09-30-2015 10-Q
36 08-13-2015 06-30-2015 10-Q
37 05-21-2015 03-31-2015 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

hc-wainwright--co-reiterates-buy-on-kalvista-pharma-maintains-20-price-target
HC Wainwright & Co. Reiterates Buy on KalV...
07/15/2024 10:42:20

HC Wainwright & Co. analyst Andrew Fein reiterates KalVista Pharma (NASDAQ:KALV) with a Buy and maintains $20 price target.

nvidia-to-rally-more-than-33-here-are-10-top-analyst-forecasts-for-friday
NVIDIA To Rally More Than 33%? Here Are 10...
07/12/2024 13:01:36

needham-maintains-buy-on-kalvista-pharma-lowers-price-target-to-32
Needham Maintains Buy on KalVista Pharma, ...
07/12/2024 09:37:24

Needham analyst Serge Belanger maintains KalVista Pharma (NASDAQ:KALV) with a Buy and lowers the price target from $35 to $32.

kalvista-submits-fda-application-for-sebetralstat-phase-3-trial-results-published
KalVista Submits FDA Application for Sebet...
07/11/2024 10:37:03

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV), today provided an operational update and released financial results for the fisca...

kalvista-pharma-q4-eps-102-misses-073-estimate-cash-balance-of-2104m
KalVista Pharma Q4 EPS $(1.02) Misses $(0....
07/11/2024 10:35:02

kalvista-pharmaceuticals-has-initiated-open-label-konfident-kid-trial-of-sebetralstat-in-pediatric-patients-with-hereditary-angioedema-the-trial-will-enroll-approximately-24-children-aged-2-to-11-years
KalVista Pharmaceuticals Has Initiated Ope...
06/27/2024 10:37:39

If approved, sebetralstat would be the first oral on-demand therapy in pediatric patients aged 2 – 11 years, and only the secon...

needham-reiterates-buy-on-kalvista-pharma-maintains-35-price-target
Needham Reiterates Buy on KalVista Pharma,...
06/18/2024 14:45:59

Needham analyst Serge Belanger reiterates KalVista Pharma (NASDAQ:KALV) with a Buy and maintains $35 price target.

kalvista-submits-new-drug-application-for-fda-review-of-sebetralstat
KalVista Submits New Drug Application For ...
06/18/2024 10:32:18

Sebetralstat is a novel investigational oral plasma kallikrein inhibitor for the on-demand treatment of hereditary angioedema (...

kalvista-pharmaceuticals-presented-us-subgroup-analysis-from-sebetralstat-phase-3-konfident-trial-real-world-claims-and-patient-survey-data-at-eastern-allergy-conference-2024-and-japanese-subgroup-at-annual-meeting-of-japanese-dermatological-association
KalVista Pharmaceuticals Presented US Subg...
06/06/2024 10:35:57

kalvista-highlights-real-world-data-on-hae-treatments-and-patient-experiences-at-eaaci-congress
KalVista Highlights Real-World Data on HAE...
06/03/2024 10:36:32

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV), today announced that it presented real-world data from US patient surveys that as...

kalvista-pharmaceuticals-presents-late-breaking-phase-3-konfident-trial-data-on-sebetralstat-at-eaaci-congress-nejm-publication-highlights-9-minute-median-time-to-treatment-and-13-hour-symptom-relief-for-laryngeal-attacks-in-konfident-s-trial
KalVista Pharmaceuticals Presents Late-Bre...
05/31/2024 16:17:25

kalvista-pharmaceuticals-says-that-ten-abstracts-accepted-for-presentation-at-the-european-academy-of-allergy-and-clinical-immunology-congress-2024
KalVista Pharmaceuticals Says That Ten Abs...
05/24/2024 10:32:32

The European Academy of Allergy and Clinical Immunology (EAACI) Congress 2024 is taking place in Valencia, Spain from May 31-Ju...

hc-wainwright--co-maintains-buy-on-kalvista-pharma-lowers-price-target-to-20
HC Wainwright & Co. Maintains Buy on KalVi...
05/03/2024 19:44:50

HC Wainwright & Co. analyst Andrew Fein maintains KalVista Pharma (NASDAQ:KALV) with a Buy and lowers the price target f...

needham-reiterates-buy-on-kalvista-pharma-maintains-35-price-target
Needham Reiterates Buy on KalVista Pharma,...
05/01/2024 16:14:49

Needham analyst Serge Belanger reiterates KalVista Pharma (NASDAQ:KALV) with a Buy and maintains $35 price target.

kalvista-pharmaceuticals-announced-its-strategic-plans-for-fiscal-year-2025-beginning-may-1-including-for-sebetralstat-the-companys-investigational-novel-oral-plasma-kallikrein-inhibitor-for-the-on-demand-treatment-of-hereditary-angioedema
Kalvista Pharmaceuticals Announced Its Str...
05/01/2024 10:38:07

needham-reiterates-buy-on-kalvista-pharma-maintains-35-price-target
Needham Reiterates Buy on KalVista Pharma,...
04/11/2024 10:07:50

Needham analyst Serge Belanger reiterates KalVista Pharma (NASDAQ:KALV) with a Buy and maintains $35 price target.

kalvista-pharmaceuticals-presented-multiple-analyses-of-the-relationship-between-the-time-to-attack-treatment-and-the-effects-delays-in-treatment-have-on-clinical-outcomes-of-hereditary-angioedema-at-the-2024-haei-regional-conference-americas
KalVista Pharmaceuticals Presented Multipl...
03/18/2024 10:46:21

hc-wainwright--co-reiterates-buy-on-kalvista-pharma-maintains-24-price-target
HC Wainwright & Co. Reiterates Buy on KalV...
03/12/2024 10:56:25

HC Wainwright & Co. analyst Andrew Fein reiterates KalVista Pharma (NASDAQ:KALV) with a Buy and maintains $24 price target.

kalvista-pharmaceuticals-announced-the-uk-medicines-and-healthcare-products-regulatory-agency-has-awarded-the-promising-innovative-medicine-designation-for-sebetralstat-for-on-demand-treatment-of-hereditary-angioedema
KalVista Pharmaceuticals Announced The UK ...
03/12/2024 10:38:04

needham-maintains-buy-on-kalvista-pharma-maintains-35-price-target
Needham Maintains Buy on KalVista Pharma, ...
03/11/2024 19:52:58

Needham analyst Serge Belanger maintains KalVista Pharma (NASDAQ:KALV) with a Buy and maintains $35 price target.

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

07/22/2024 Cambium Networks Corporation (CMBM)
07/22/2024 Biogen Inc. (BIIB)
07/23/2024 Fastly, Inc. (FSLY)
07/29/2024 Enphase Energy, Inc. (ENPH)
07/30/2024 Rivian Automotive, Inc. (RIVN)
07/30/2024 Hertz Global Holdings, Inc. (HTZ)
08/02/2024 Humana Inc. (HUM)
08/05/2024 Marinus Pharmaceuticals, Inc. (MRNS)

NEW CASE INVESTIGATION

Ooma Inc (OOMA) AnaptysBio Inc (ANAB)